HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead

Core Insights - HOOKIPA Pharma Inc. has completed the sale of its assets related to the HB-400 and certain assets related to the HB-500 programs to Gilead Sciences, Inc. [1][2] - The asset purchase agreement was entered into on May 21, 2025, and the closing occurred on October 30, 2025 [2]. Group 1 - The HB-400 program is currently in clinical development for the treatment of hepatitis B virus [2]. - The HB-500 program is currently in clinical development for the treatment of human immunodeficiency virus [2]. - HOOKIPA has been developing both programs in collaboration with Gilead under a collaboration and license agreement [2]. Group 2 - HOOKIPA's board of directors evaluated the long-term prospects and strategies leading to the asset sale [2]. - The company utilizes various channels, including its investor relations website and social media, to communicate material financial information to investors [3]. - Investors are encouraged to review the information posted on social media channels listed on HOOKIPA's investor relations website [3].